Other Species / Isoforms
  EZH2 (mouse)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
K7
_MGQTGKKSEKGPVC
0 1
EZH2 (human) _MGQTGKksEkGPVC K7-ub
EZH2 iso2 (human) _MGQTGKKSEKGPVC K7
EZH2 (mouse) _MGQTGKKSEKGPVC K7
EZH2 (rat) _MGQTGKKSEKGPVC K7
S8
MGQTGKKSEKGPVCW
0 1
EZH2 (human) MGQTGKksEkGPVCW S8-p
EZH2 iso2 (human) MGQTGKKSEKGPVCW S8
EZH2 (mouse) MGQTGKKSEKGPVCW S8
EZH2 (rat) MGQTGKKSEKGPVCW S8
K10
QTGKKSEKGPVCWRK
0 2
EZH2 (human) QTGKksEkGPVCWRK K10-ub
EZH2 iso2 (human) QTGKKSEKGPVCWRK K10
EZH2 (mouse) QTGKKSEKGPVCWRK K10
EZH2 (rat) QTGKKSEKGPVCWRK K10
S21
CWRKRVKSEYMRLRQ
4 1
EZH2 (human) CWRKRVKsEyMRLRQ S21-p
EZH2 iso2 (human) CWRKRVKSEYMRLRQ S21
EZH2 (mouse) CWRKRVKSEYMRLRQ S21
EZH2 (rat) CWRKRVKSEYMRLRQ S21
Y23
RKRVKSEYMRLRQLK
0 1
EZH2 (human) RKRVKsEyMRLRQLK Y23-p
EZH2 iso2 (human) RKRVKSEYMRLRQLK Y23
EZH2 (mouse) RKRVKSEYMRLRQLK Y23
EZH2 (rat) RKRVKSEYMRLRQLK Y23
K39
FRRADEVKTMFSSNR
0 1
EZH2 (human) FRRADEVkSMFSSNR K39-ub
EZH2 iso2 (human) FRRADEVKSMFSSNR K39
EZH2 (mouse) FRRADEVKTMFSSNR K39
EZH2 (rat) FRRADEVKTMFSSNR K39
K61
ETLNQEWKQRRIQPV
0 5
EZH2 (human) EILNQEWkQRRIQPV K61-ub
EZH2 iso2 (human) EILNQEWKQRRIQPV K61
EZH2 (mouse) ETLNQEWKQRRIQPV K61
EZH2 (rat) ETLNQEWKQRRIQPV K61
S76
HIMTSVSSLRGTREC
0 1
EZH2 (human) HILTSVSsLRGTREC S76-p
EZH2 iso2 (human) HILTSVSSLRGTREC S76
EZH2 (mouse) HIMTSVSSLRGTREC S76
EZH2 (rat) HIMTSVSSLRGTREC S76
S76
HIMTSVSSLRGTREC
1 0
EZH2 (human) HILTSVSsLRGTREC S76-gl
EZH2 iso2 (human) HILTSVSSLRGTREC S76
EZH2 (mouse) HIMTSVSSLRGTREC S76
EZH2 (rat) HIMTSVSSLRGTREC S76
T212
DNRDDKETCPPRKFP
0 2
EZH2 (human) DHRDDKEsRPPRKFP S212-p
EZH2 iso2 (human) DHRDDKESRPPRKFP S212
EZH2 (mouse) DNRDDKETCPPRKFP T212
EZH2 (rat) DSRDDKETCPPRKFP T212
A220
CPPRKFPADKIFEAI
1 2
EZH2 (human) RPPRKFPsDKIFEAI S220-p
EZH2 iso2 (human) RPPRKFPSDKIFEAI S220
EZH2 (mouse) CPPRKFPADKIFEAI A220
EZH2 (rat) CPPRKFPADKIFEAI A220
K234
ISSMFPDKGTAEELK
0 1
EZH2 (human) ISSMFPDkGTAEELK K234-ac
EZH2 iso2 (human) ISSMFPDKGTAEELK K234
EZH2 (mouse) ISSMFPDKGTAEELK K234
EZH2 (rat) ISSMFPDKGTAEELK K234
K234
ISSMFPDKGTAEELK
0 1
EZH2 (human) ISSMFPDkGTAEELK K234-ub
EZH2 iso2 (human) ISSMFPDKGTAEELK K234
EZH2 (mouse) ISSMFPDKGTAEELK K234
EZH2 (rat) ISSMFPDKGTAEELK K234
Y244
AEELKEKYKELTEQQ
2 0
EZH2 (human) AEELKEKyKELTEQQ Y244-p
EZH2 iso2 (human) AEELKEKYKELTEQQ Y244
EZH2 (mouse) AEELKEKYKELTEQQ Y244
EZH2 (rat) AEELKEKYKELTEQQ Y244
T261
GALPPECTPNIDGPN
1 0
EZH2 (human) GALPPECtPNIDGPN T261-p
EZH2 iso2 (human) GALPPECTPNIDGPN T261
EZH2 (mouse) GALPPECTPNIDGPN T261
EZH2 (rat) GALPPECTPNIDGPN T261
T302
FLHPFHATPNTYKRk
0 4
EZH2 (human) FLHPFHAtPNtYKRK T302-p
EZH2 iso2 (human) CNYSFHATPNTYKRK T307
EZH2 (mouse) FLHPFHATPNTYKRk T302
EZH2 (rat) FLHPFHATPNTYKRK T302
T305
PFHATPNTYKRkNTE
0 1
EZH2 (human) PFHAtPNtYKRKNtE T305-p
EZH2 iso2 (human) SFHATPNTYKRKNTE T310
EZH2 (mouse) PFHATPNTYKRkNTE T305
EZH2 (rat) PFHATPNTYKRKNTE T305
K309-ac
TPNTYKRkNTETALD
0 1
EZH2 (human) tPNtYKRKNtETALD K309
EZH2 iso2 (human) TPNTYKRKNTETALD K314
EZH2 (mouse) TPNTYKRkNTETALD K309-ac
EZH2 (rat) TPNTYKRKNTETALD K309
T311
NTYKRkNTETALDNK
1 1
EZH2 (human)
T311-p
EZH2 iso2 (human)
T316-p
EZH2 (mouse)
T311-p
EZH2 (rat)
T311-p
EZH2 (human) NtYKRKNtETALDNk T311-p
EZH2 iso2 (human) NTYKRKNTETALDNK T316
EZH2 (mouse) NTYKRkNTETALDNK T311
EZH2 (rat) NTYKRKNTETALDNK T311
K318
TETALDNKPCGPQCY
0 1
EZH2 (human) tETALDNkPCGPQCY K318-ub
EZH2 iso2 (human) TETALDNKPCGPQCY K323
EZH2 (mouse) TETALDNKPCGPQCY K318
EZH2 (rat) TETALDNKPCGPQCY K318
T339-p
KEFAAALtAERIKtP
0 7
EZH2 (human) KEFAAALtAERIKtP T339-p
EZH2 iso2 (human) KEFAAALTAERIKTP T344
EZH2 (mouse) KEFAAALtAERIKtP T339-p
EZH2 (rat) KEFAAALTAERIKTP T339
T345-p
LtAERIKtPPKRPGG
Upstream
Downstream
8 13
Effects on Modified Protein
  • molecular association, regulation
  • protein degradation
Kinase, in vitro:
  • CDK1 (human)
Regulatory protein:
  • NIPP-1 (human)
  • PPP1CA (human)
Treatment
  • etoposide
  • olomoucine
  • seliciclib
EZH2 (human) LtAERIKtPPkRPGG T345-p
EZH2 iso2 (human) LTAERIKTPPKRPGG T350
EZH2 (mouse) LtAERIKtPPKRPGG T345-p
EZH2 (rat) LTAERIKTPPKRPGG T345
K348
ERIKtPPKRPGGRRR
1 0
EZH2 (human) ERIKtPPkRPGGRRR K348-ac
EZH2 iso2 (human) ERIKTPPKRPGGRRR K353
EZH2 (mouse) ERIKtPPKRPGGRRR K348
EZH2 (rat) ERIKTPPKRPGGRRR K348
S362-p
RGRLPNNssRPstPt
1 13
EZH2 (human) RGRLPNNssRPstPt S362-p
EZH2 iso2 (human) RGRLPNNSSRPSTPT S367
EZH2 (mouse) RGRLPNNssRPstPt S362-p
EZH2 (rat) RGRLPNNSsRPStPt S362
S363-p
GRLPNNssRPstPtI
1 40
EZH2 (human) GRLPNNssRPstPtI S363-p
EZH2 iso2 (human) GRLPNNSSRPSTPTI S368
EZH2 (mouse) GRLPNNssRPstPtI S363-p
EZH2 (rat) GRLPNNSsRPStPtI S363-p
S366-p
PNNssRPstPtISVL
1 37
EZH2 (human) PNNssRPstPtINVL S366-p
EZH2 iso2 (human) PNNSSRPSTPTINVL S371
EZH2 (mouse) PNNssRPstPtISVL S366-p
EZH2 (rat) PNNSsRPStPtIsVL S366
T367-p
NNssRPstPtISVLE
2 63
EZH2 (human) NNssRPstPtINVLE T367-p
EZH2 iso2 (human) NNSSRPSTPTINVLE T372
EZH2 (mouse) NNssRPstPtISVLE T367-p
EZH2 (rat) NNSsRPStPtIsVLE T367-p
T369-p
ssRPstPtISVLESK
0 12
EZH2 (human) ssRPstPtINVLEsK T369-p
EZH2 iso2 (human) SSRPSTPTINVLESK T374
EZH2 (mouse) ssRPstPtISVLESK T369-p
EZH2 (rat) SsRPStPtIsVLESK T369-p
S371
RPstPtISVLESKDT
0 1
EZH2 (human) RPstPtINVLEsKDT N371
EZH2 iso2 (human) RPSTPTINVLESKDT N376
EZH2 (mouse) RPstPtISVLESKDT S371
EZH2 (rat) RPStPtIsVLESKDT S371-p
S375
PtISVLESKDTDsDR
0 1
EZH2 (human) PtINVLEsKDTDsDR S375-p
EZH2 iso2 (human) PTINVLESKDTDSDR S380
EZH2 (mouse) PtISVLESKDTDsDR S375
EZH2 (rat) PtIsVLESKDTDsDR S375
S380-p
LESKDTDsDREAGTE
Upstream
0 7
Treatment
  • insulin
EZH2 (human) LEsKDTDsDREAGTE S380-p
EZH2 iso2 (human) LESKDTDSDREAGTE S385
EZH2 (mouse) LESKDTDsDREAGTE S380-p
EZH2 (rat) LESKDTDsDREAGTE S380-p
T388
DREAGTETGGENNDK
0 2
EZH2 (human) DREAGTEtGGENNDK T388-p
EZH2 iso2 (human) DREAGTETGGENNDK T393
EZH2 (mouse) DREAGTETGGENNDK T388
EZH2 (rat) DREAGTETGGENNDK T388
S405
EEKKDETSSSsEANs
0 1
EZH2 (human) EEKKDETssSsEANs S405-p
EZH2 iso2 (human) EEKKDETSSSSEANS S410
EZH2 (mouse) EEKKDETSSSsEANs S405
EZH2 (rat) EEKKDETSSSSEANS S405
S406
EKKDETSSSsEANsR
0 3
EZH2 (human) EKKDETssSsEANsR S406-p
EZH2 iso2 (human) EKKDETSSSSEANSR S411
EZH2 (mouse) EKKDETSSSsEANsR S406
EZH2 (rat) EKKDETSSSSEANSR S406
S408-p
KDETSSSsEANsRCQ
0 2
EZH2 (human) KDETssSsEANsRCQ S408-p
EZH2 iso2 (human) KDETSSSSEANSRCQ S413
EZH2 (mouse) KDETSSSsEANsRCQ S408-p
EZH2 (rat) KDETSSSSEANSRCQ S408
S412-p
SSSsEANsRCQtPIK
0 6
EZH2 (human) ssSsEANsRCQtPIK S412-p
EZH2 iso2 (human) SSSSEANSRCQTPIK S417
EZH2 (mouse) SSSsEANsRCQtPIK S412-p
EZH2 (rat) SSSSEANSRCQTPIK S412
T416-p
EANsRCQtPIKMKPN
Upstream
Downstream
5 11
Effects on Modified Protein
  • activity, induced
Effects on Biological Processes:
  • carcinogenesis, induced
Putative in vivo kinases:
  • CDK2 (human)
Treatment
  • dinaciclib
EZH2 (human) EANsRCQtPIKMKPN T416-p
EZH2 iso2 (human) EANSRCQTPIKMKPN T421
EZH2 (mouse) EANsRCQtPIKMKPN T416-p
EZH2 (rat) EANSRCQTPIKMKPN T416
T460
AIARLIGTKTCRQVY
0 1
EZH2 (human) AIARLIGtkTCRQVY T460-p
EZH2 iso2 (human) AIARLIGTKTCRQVY T465
EZH2 (mouse) AIARLIGTKTCRQVY T460
EZH2 (rat) AIARLIGTKTCRQVY T460
K461
IARLIGTKTCRQVYE
0 1
EZH2 (human) IARLIGtkTCRQVYE K461-ub
EZH2 iso2 (human) IARLIGTKTCRQVYE K466
EZH2 (mouse) IARLIGTKTCRQVYE K461
EZH2 (rat) IARLIGTKTCRQVYE K461
K472
QVYEFRVKESSIIAP
0 2
EZH2 (human) QVYEFRVkESSIIAP K472-ub
EZH2 iso2 (human) QVYEFRVKESSIIAP K477
EZH2 (mouse) QVYEFRVKESSIIAP K472
EZH2 (rat) QVYEFRVKESSIIAP K472
T487-p
VPTEDVDtPPRKKKR
Upstream
Downstream
8 118
Effects on Modified Protein
  • protein degradation
Kinase, in vitro:
  • CDK1 (human)
Regulatory protein:
  • NIPP-1 (human)
  • PPP1CA (human)
EZH2 (human) APAEDVDtPPRKKKR T487-p
EZH2 iso2 (human) APAEDVDTPPRKKKR T492
EZH2 (mouse) VPTEDVDtPPRKKKR T487-p
EZH2 (rat) VPTEDVDtPPRKKKR T487-p
K505
LWAAHCRKIQLKKDG
0 3
EZH2 (human) LWAAHCRkIQLkkDG K505-m2
EZH2 iso2 (human) LWAAHCRKIQLKKDG K510
EZH2 (mouse) LWAAHCRKIQLKKDG K505
EZH2 (rat) LWAAHCRKIQLKKDG K505
K509
HCRKIQLKKDGSSNH
0 1
EZH2 (human) HCRkIQLkkDGSSNH K509-m2
EZH2 iso2 (human) HCRKIQLKKDGSSNH K514
EZH2 (mouse) HCRKIQLKKDGSSNH K509
EZH2 (rat) HCRKIQLKKDGSSNH K509
K510
CRKIQLKKDGSSNHV
0 3
EZH2 (human) CRkIQLkkDGSSNHV K510-m2
EZH2 iso2 (human) CRKIQLKKDGSSNHV K515
EZH2 (mouse) CRKIQLKKDGSSNHV K510
EZH2 (rat) CRKIQLKKDGSSNHV K510
T568-p
RCKAQCNtKQCPCYL
0 1
EZH2 (human) RCKAQCNTkQCPCYL T568
EZH2 iso2 (human) RCKAQCNTKQCPCYL T573
EZH2 (mouse) RCKAQCNtKQCPCYL T568-p
EZH2 (rat) RCKAQCNTKQCPCYL T568
K569
CKAQCNtKQCPCYLA
0 3
EZH2 (human) CKAQCNTkQCPCYLA K569-ub
EZH2 iso2 (human) CKAQCNTKQCPCYLA K574
EZH2 (mouse) CKAQCNtKQCPCYLA K569
EZH2 (rat) CKAQCNTKQCPCYLA K569
K597
AADHWDSKNVSCKNC
0 1
EZH2 (human) AADHWDSkNVSCkNC K597-ub
EZH2 iso2 (human) AADHWDSKNVSCKNC K602
EZH2 (mouse) AADHWDSKNVSCKNC K597
EZH2 (rat) AADHWDSKNVSCKNC K597
K602
DSKNVSCKNCSIQRG
0 2
EZH2 (human) DSkNVSCkNCSIQRG K602-ub
EZH2 iso2 (human) DSKNVSCKNCSIQRG K607
EZH2 (mouse) DSKNVSCKNCSIQRG K602
EZH2 (rat) DSKNVSCKNCSIQRG K602
K629
AGWGIFIKDPVQKNE
0 1
EZH2 (human) AGWGIFIkDPVQkNE K629-ub
EZH2 iso2 (human) AGWGIFIKDPVQKNE K634
EZH2 (mouse) AGWGIFIKDPVQKNE K629
EZH2 (rat) AGWGIFIKDPVQKNE K629
K634
FIKDPVQKNEFISEY
0 1
EZH2 (human) FIkDPVQkNEFISEy K634-ub
EZH2 iso2 (human) FIKDPVQKNEFISEY K639
EZH2 (mouse) FIKDPVQKNEFISEY K634
EZH2 (rat) FIKDPVQKNEFISEY K634
Y641
KNEFISEYCGEIISQ
1 0
EZH2 (human) kNEFISEyCGEIISQ Y641-p
EZH2 iso2 (human) KNEFISEYCGEIIsQ Y646
EZH2 (mouse) KNEFISEYCGEIISQ Y641
EZH2 (rat) KNEFISEYCGEIISQ Y641
S647
EYCGEIISQDEADRR
1 0
EZH2 (human) EyCGEIISQDEADRR S647
EZH2 iso2 (human) EYCGEIIsQDEADRR S652-p
EZH2 (mouse) EYCGEIISQDEADRR S647
EZH2 (rat) EYCGEIISQDEADRR S647
S690
KIRFANHSVNPNCyA
0 1
EZH2 (human) KIRFANHsVNPNCyA S690-p
EZH2 iso2 (human) KIRFANHSVNPNCYA S695
EZH2 (mouse) KIRFANHSVNPNCyA S690
EZH2 (rat) KIRFANHSVNPNCYA S690
Y696-p
HSVNPNCyAKVMMVN
Upstream
Downstream
1 2
Effects on Modified Protein
  • enzymatic activity, inhibited
  • molecular association, regulation
Effects on Biological Processes:
  • apoptosis, inhibited
  • carcinogenesis, induced
  • cell growth, induced
  • signaling pathway regulation
  • transcription, induced
Putative in vivo kinases:
  • Src iso1 (mouse)
Treatment
  • saracatinib
  • siRNA
EZH2 (human) HsVNPNCyAKVMMVN Y696-p
EZH2 iso2 (human) HSVNPNCYAKVMMVN Y701
EZH2 (mouse) HSVNPNCyAKVMMVN Y696-p
EZH2 (rat) HSVNPNCYAKVMMVN Y696
T718
FAKRAIQTGEELFFD
0 1
EZH2 (human) FAKRAIQtGEELFFD T718-p
EZH2 iso2 (human) FAKRAIQTGEELFFD T723
EZH2 (mouse) FAKRAIQTGEELFFD T718
EZH2 (rat) FAKRAIQTGEELFFD T718
S729
LFFDYRYSQADALKY
1 0
EZH2 (human) LFFDYRYSQADALKY S729
EZH2 iso2 (human) LFFDYRYsQADALKY S734-p
EZH2 (mouse) LFFDYRYSQADALKY S729
EZH2 (rat) LFFDYRYSQADALKY S729